Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis

Abstract

ChEIs and atypical antipsychotics could improve neuropsychiatric symptoms in AD patients, but with bad safety outcomes.

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysis

“…To our knowledge, this is the first NMA of ChEIs treatment in patients with AD in which compared using both direct and indirect comparisons of interventions across trials simultaneously. This should strengthen the findings from our analysis over previous meta‐analyses (Trinh et al , 2003; Birks, 2006; Hansen et al , 2008; Lockhart et al , 2011;Tan et al , 2014; Wang et al , 2014). The study quality of head‐to‐head trials might be questionable, because two out of three head‐to‐head trials were not double‐blinded.…”

“…We excluded trials enrolling patients with severe AD. Conversely, recent meta‐analyses include severe AD (Hansen et al , 2008; Di Santo et al , 2013; Tan et al , 2014, Wang et al , 2014). Although a previous meta‐analysis Di Santo et al (2013) documented no relationship between severity of dementia and efficacy of ChEIs on neuropsychiatric symptoms, patients with AD deteriorate progressively and may present with varying degrees of severity of disease, which may influence the results from pooled data.…”

“…To date, several reviews and meta‐analyses have been published summarising the efficacy and safety of second‐generation ChEIs for treatment of AD (Trinh et al , 2003; Birks, 2006; Hansen et al , 2008; Tan et al , 2014; Wang et al , 2014). However, comparative evidence is still sparse.…”

Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery

“…For example, Parkinson's is commonly associated with co-morbid depression, anxiety, and apathy, as well as cognitive psychosis (Cooney and Stacy, 2016;Holden et al, 2016). Neuropsychiatric symptoms are common in Alzheimer's disease (Spalletta et al, 2010), and treated pharmacologically with variable results (Wang et al, 2015a). Impairments in cognition are common across neuropsychiatric disorders, (Henry et al, 2016) and are severe unmet medical needs (Millan et al, 2012).…”

Cognitive and non-cognitive neuropsychiatric disorders in dementia and methods of their correction

“…Метаанализ рандомизированных клинических иссле-дований, в которых сравнивалось действие фармакологиче-ских агентов при БА с наличием некогнитивных симптомов, позволил заключить, что терапия ингибиторами ацетил-холинэстеразы и атипичными антипсихотическими препара-тами улучшает нейропсихические симптомы по шкале NPI, однако при этом отмечен плохой профиль безопасности [59].…”